Oncolytics Biotech Inc. (TSE:ONC – Get Free Report)’s stock price traded down 1.6% on Thursday . The company traded as low as C$1.18 and last traded at C$1.20. 123,141 shares were traded during trading, an increase of 72% from the average session volume of 71,561 shares. The stock had previously closed at C$1.22.
Analysts Set New Price Targets
Separately, Raymond James raised Oncolytics Biotech to a “moderate buy” rating in a research note on Thursday, November 14th.
Check Out Our Latest Report on ONC
Oncolytics Biotech Stock Down 1.6 %
About Oncolytics Biotech
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Featured Articles
- Five stocks we like better than Oncolytics Biotech
- Differences Between Momentum Investing and Long Term Investing
- WallStreetBets: How a Reddit Forum Shook Up Stock Market Dynamics
- 3 Healthcare Dividend Stocks to Buy
- Are 2024’s Top Insider Buys a Good Bet for 2025?
- Utilities Stocks Explained – How and Why to Invest in Utilities
- 4 Social Media Stocks to Soar as TikTok’s Future Hangs in Balance
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.